

Financial Tear Sheet

Corporate Profile

Iovance Biotherapeutics (formerly traded as Lion Biotechnologies) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). This approach, also known as adoptive T-cell therapy, was developed by Dr. Steven A. Rosenberg at the National Cancer Institute. In Phase 2 clinical trials conducted at the NCI, 56% and 24% of patients treated with this technology achieved objective and complete response criteria, respectively.

Our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma.

In addition to metastatic malignant melanoma, carcinoma of the head and neck and cervical cancer our TIL therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. As we continue advancing our current clinical programs through the introduction of manufacturing and logistical efficiencies aimed at decreasing production time and optimizing distribution processes, we aim to establish TIL therapy as a revolutionary, accessible, mainline cancer therapy.

Primary IR Contact

Stern Investor Relations, Inc.

Sarah McCabe

Phone: 212-362-1200

E-mail:

sarah@sternir.com

Stock Performance

IOVA (Common Stock)

Exchange NASDAQ (US Dollar)

Price **\$7.23**

Change (%) 0.00 (0.00%)

Volume 330,494

52 Week High \$8.60

52 Week Low \$4.45

Market Cap \$508,442,743

Rolling EPS -2.11

PE Ratio 0

Shares Outstanding 70,372,698

Data as of October 20, 2017 4:00 p.m. ET



Recent Headlines

October 11, 2017

[Iovance Biotherapeutics Announces Six Abstracts to be Presented at the Upcoming 2017 SITC Annual Meeting](#)

September 25, 2017

[Iovance Biotherapeutics, Inc. Announces Closing of \\$57.5 Million Common Stock Public Offering](#)

September 20, 2017

[Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of \\$50 Million of Common Stock](#)

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
October 20, 2017	3
September 28, 2017	CT ORDER
September 26, 2017	8-K
September 21, 2017	8-K

Corporate Governance

Data provided by Nasdaq. Minimum 15 minutes delayed.

© 2017 Lion Biotechnologies, Inc. All Rights Reserved.